TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›IBEX›Financials
Annual statements · SEC XBRL · FY2021 – FY2025

IBEX Ltd (IBEX) financials

Income statement

IBEX Ltd (IBEX) income statement, annual, from SEC filings
Fiscal yearFY2021FY2022FY2023FY2024FY2025
Revenue$443M$493M$523M$509M$558M
Revenue growth—11.2%6.1%-2.8%9.8%
Operating income$17.0M$20.6M$40.5M$39.4M$46.6M
Operating margin3.8%4.2%7.7%7.8%8.3%
Net income$13.1M$21.5M$31.6M$33.7M$36.9M
Net margin3.0%4.4%6.0%6.6%6.6%
EPS (diluted)$0.71$1.15$1.67$1.84$2.36

Cash flow

IBEX Ltd (IBEX) cash flow, annual, from SEC filings
Fiscal yearFY2021FY2022FY2023FY2024FY2025
Operating cash flow$16.1M$40.0M$41.9M$35.9M$45.7M
Capital expenditures$20.8M$25.9M$19.0M$8.86M$18.4M
Free cash flow-$4.75M$14.1M$22.9M$27.0M$27.3M
Share buybacks$0.00$3.41M$276K$21.6M$78.0M
Dividends paid$4.00M$0.00$0.00——

Balance sheet

IBEX Ltd (IBEX) balance sheet, annual, from SEC filings
Fiscal yearFY2021FY2022FY2023FY2024FY2025
Cash & equivalents$57.8M$48.8M$57.4M$62.7M$15.3M
Total assets—$294M$293M$294M$273M
Total liabilities—$181M$143M$128M$139M
Shareholders' equity$94.7M$113M$150M$166M$134M
Retained earnings—-$76.4M-$44.8M-$11.1M$25.7M
Shares (wtd avg diluted)18.4M18.7M18.9M18.3M15.7M

Every figure is extracted from IBEX Ltd’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

What is IBEX Ltd's annual revenue?
IBEX Ltd (IBEX) reported $558M of revenue for fiscal year 2025 — up 9.8% from $509M in FY2024, per its annual report filed with the SEC.
Is IBEX Ltd profitable?
Yes — IBEX earned $36.9M of net income in FY2025, a 6.6% net margin, per SEC filings.
What is IBEX Ltd's free cash flow?
$27.3M in FY2025 (operating cash flow $45.7M minus $18.4M of capital expenditures), from the SEC cash-flow statement.
Does IBEX pay a dividend?
IBEX Ltd reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full IBEX analysis — verdict, score & filings →Is IBEX a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.